Company intelligence / Profile preview
MDimune Inc.
- Ownership
- Private
- Development stage
- Preclinical
Overview
MDimune has demonstrated preclinical efficacy of its MSC-CDV therapeutics in multiple disease models including cancer and inflammatory conditions. The company has developed a GMP-compliant manufacturing process for CDVs with high yield and functional similarity to natural EVs. Clinical trials are anticipated soon but no human data yet published as of early 2024
- Therapeutic areas
- GastroenterologyCardiovascularOphthalmologyImmunologyOncologyNeurology
- Modalities
- cell-derived vesicles (CDVs)extracellular vesicles (EVs)mRNAmiRNAmesenchymal stem cell therapybiological products
- Industry
- Biotech
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on MDimune Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MDimune Inc..